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Abstract. Myeloid sarcoma (extramedullary myeloblastoma, granulocytic sarcoma, chloroma) is an extramedullary isolated malignant 
tumor of myeloblasts and immature myelocytes. It can occur anywhere in the body as a solitary tumor or can be accompanied with acute 
myeloid leukemia. We are presenting a case of a young male patient that presented with sings of a small bowel obstruction and a palpable 
tumor mass in the abdomen. After uneventful postoperative period, the immunohistochemistry analysis reported an extramedullary 
myeloid sarcoma since a normal bone marrow biopsy was revealed.
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Introduction
Myeloid sarcoma (extramedullary myeloblastoma, granulocytic sarcoma, chloroma) is an extramedullary 
isolated malignant tumor of myeloblasts and immature myelocytes [1]. It can occur anywhere in the body 
affecting only one or sometimes more than two different organs (skin, gastrointestinal system, lymph nodes, 
central nervous system, heart) [2–4]. The myeloid sarcoma (MS) is often accompanied (as a relapse) or fol-
lowed by acute myeloid leukemia (AML). It can also precede other blood or bone marrow disease [5]. Ac-
cording to the 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms 
and acute leukemia, the MS is classified in the group of myeloid neoplasms and acute leukemia, subgroup 
of acute myeloid leukemia and related neoplasms [5].
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MS occurs in patients with AML in 2–8% of cases [6]. Due to its low incidence, only small series and case 
reports are published. The age of the affected patients is variable due to the reported cases.
The clinical presentation of the extramedullary isolated tumor is dependent of its localization. The domi-
nating clinical signs are associated with compressive effects, localized pain and bleeding. Therefore, contrast 
enhanced computer tomography (CT) and magnetic resonance imaging (MRi) are mostly used for the initial 
diagnosis [7].
The final diagnosis of MS is established with immunohistochemistry and immunophe-notyping [8].
Since there is a lack of a consensus for the treatment of MS, the proposed treatment whether for extra-
medullary MS or the one that is concomitant with AML is the standard AML-type chemotherapy, hemato-
poietic stem-cell transplanation and radiotherapy [8]. There are also reports for targeted therapy with new 
drugs such as: monoclonal antibody therapy with Gemtuzumab ozogamicin, Nucleoside analogues, demethy-
altion agents and others [6, 9, 10].
If left untreated, the extramedullary MS almost always progresses to AML. The prognosis for this condition 
is variable but similar to that of AML [11].
Case report
In May 2018, a 22 years old male patient presented to our emergency department of surgery with clinical 
signs of intestinal obstruction accompanied with abdominal pain and vomiting. On a physical examination 
the abdomen was slightly distended and with palpable tumor in the right medial abdominal quadrant. The 
blood analysis showed normal leukocyte count of 7.0x109/l with differential count for Lymphocytes 24.2%, 
Monocytes 13.3% and Neutrophils 62.5%. Platelets count was 447x109/l, hemoglobin level of 158.0x109/l 
and CRP level of 4.4 mg/l.
The plain radiograph showed signs of small bowel obstruction (Figure 1).
Figure 1
A contrast enhanced CT scan was indicated due to the palpable abdominal tumor and it revealed a forma-
tion that originates from the ileal mesentery involving the ileocolic artery and a part of the ileum with ileal 
wall thickening and partial obstruction (Figures 2, 3 and 4).
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   Figure 2                                                                Figure 3
Figure 4
A surgical exploration was indicated the same day. During surgery, the tumor affected part of the mesentery 
that contains the ileocolic artery but with no vascular changes of the terminal ileum and the right colon. It 
was also affecting a part of the ileum wall which explained the small bowel obstruction (Figure 5, 6).
     
Figure 5    Figure 6
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Due to the normal finding of the right colon, extirpation of the whole tumor was not attempted and 
only a resection of the affected ileum was undertaken with a primary anastomosis creation. The patient had 
uneventful postoperative period and was discharged on postoperative day 6.
The macroscopic pathology analysis revealed hemorrhagic elevations of the ileal mucosa with infiltrating 
lesion of the intestinal wall and luminal stenosis in up to 90%. The same was spreading in the mesenteric 
fat. Microscopic view showed 4–5 mitoses on large microscopic field (Figure 7).
    
Figure 7. HE staining
The immunohistochemistry analysis found high expression for Lysozime, LCA, CD117 and CD68 and 
partial expression for CD11c and bcl–2 (Figure 8).
CD11  CD68  CD138  Ki67   CD117
Figure 8. Immunohistochemistry staining
      
Figure 9. A normal finding of post-transplant PET/CT Scan
59
Klinikinė praktika / Andrej Nikolovski, Dragoslav Mladenovikj, Aleksandra Veljanovska, Gordana Petrusevka 
Primary myeloid sarcoma of the ileum and mesentery causing small bowel obstruction: case report and literature review
During the immunohistochemistry analysis, the patient was sent to the University Clinic for Hematology 
where a bone marrow biopsy was done. It showed no signs of leukemic process and the diagnosis of extra-
medullary myeloid sarcoma was established.
In the same time period (one month after the surgery), the patient developed AML and was admitted 
to the University Clinic for Hematology. A standard induction regimen therapy (7+3) was conducted and 
afterwards allogenic bone marrow transplant was performed at the Clinic for Hematology. The recovery 
period were uneventful.
One year after the operation, a PET/ CT scan performed showed normal distribution of F-18 FDG and 
no signs of residual intraabdominal tumor (Figure 9). In the present period, the patient is disease free.
Discussion
The extramedullary myeloid sarcoma with primary localization in the gastrointestinal system is rare and ac-
counts with 6.5% of cases where the ileum is the most common site affected [12, 13]. The literature review 
reveals mostly single case reports [14–24]. Establishing its diagnosis is difficult. An isolated MS that can be 
misdiagnosed initially in up to 47% with some other hematologic malignancies, mostly malignant lymphoma 
[25]. The presence of MS with normal bone marrow finding has been reported in 30% of cases [26]. It 
certainly contributes for the diagnosis delay and postpones the beginning of the appropriate therapy. In our 
case the patient’s condition progressed to AML within a month after the surgery, although a previously done 
bone marrow biopsy was with normal finding.
The treatment for isolated MS or the one concomitant with AML includes a standard AML-type chemo-
therapy, since a higher rate of progression to AML in patients with isolated MS that have been treated with 
local excision only are reported [25, 27, 28].
Radiotherapy has been added in cases of MS previously treated with chemotherapy. Unfortunately no sig-
nificant effect was found in matter of prolonged survival compared to those that were not radiated [8, 27, 29].
A few retrospective reports show the role of hematopoietic stem cell transplantation. Allogenic and au-
tologous stem cell transplantation (SCT) was used in small groups of patients. In all the series, the groups 
of patients with any type of SCT reported significantly prolonged overall survival compared to those from 
non-SCT groups [6, 8].
Targeted therapy in its inception has been reported with various drugs such as Gemtuzumab ozogamicin, 
Imatinib mesylat, nucleoside analogues and demethyaltion agents [6, 9, 10, 30]. The reports are somewhere 
promising. Probably a model for identification of those patients that could have benefit is needed.
Conclusion
MS is related with uncertain prognosis and outcome. It is important to report and publish all newly diag-
nosed cases even as a case reports. It will lead, at least partially, to comprehend the clinical patterns of the 
extramedullary myeloid sarcoma. This could probably allow timely diagnosis and more efficient therapy for 
longer disease-free period and longer overall survival.
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